Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia
Brescia 25123
1 studies enrolling now · 8 studies all time
What they study most
Advanced Non-Small Cell Lung Cancer, B-Cell Non-Hodgkin Lymphoma, Castration-resistant Prostate Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Diffuse Large B-cell Lymphoma, Hepatocellular Carcinoma, Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Refractory B-Cell Non-Hodgkin Lymphoma
Studies at this site
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 — Recruiting now
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) — Running, not enrolling
- Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Running, not enrolling
- Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma — Running, not enrolling
- A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors — Stopped early
- A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) — Stopped early
- A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) — Stopped early